Moderna's stock is experiencing a notable uptick as it capitalizes on recent positive developments in its oncology pipeline.
Moderna Inc. (NASDAQ:MRNA) is rising today, gaining 1.10% to close at CA$199.45. The company's stock is benefiting from renewed investor interest following the successful results of its melanoma vaccine trials and ongoing discussions about expanding its manufacturing capabilities in the Middle East.
Advertisement
Moderna Inc
MRNA.US
MRNA.US
Moderna Inc
WealthAwesomeMarket cap
$78.76B
52W high
$202.67
52W low
$22.28
1W change
+14.07%
Beta
1.11
Analyst Price Targets
Based on 27 analysts covering MRNA · as of Sep 17, 2026
Wall Street analysts forecast MRNA stock price to fall 39.4% over the next 12 months.
Consensus
Hold3.22 / 5.00
Avg. Target
C$119.56
-39.4% Upside
Current Price
C$197.28
Last close
Analyst Breakdown (27 analysts)
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on MRNA's historical volatility
30-Day Vol
315.7%
Annualized
90-Day Vol
214.7%
Annualized
Trend (90d)
+50.0%
Annualized drift
90d Mean
C$235.85
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$209.38 | C$70.44 – C$622.37 |
| 60 trading days | C$222.22 | C$47.61 – C$1037.22 |
| 90 trading days | C$235.85 | C$35.74 – C$1556.31 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Investor takeaway: Investors are encouraged by Moderna's transition from a COVID-19-centric business model to a broader oncology and respiratory franchise, bolstered by recent trial successes and strategic partnerships.
Moderna's stock rises 1.10% today.
The stock's gain reflects a broader investor optimism about Moderna's future prospects in oncology and respiratory vaccines.
Bull case
The successful Phase 3 trial results for its melanoma vaccine and the potential for expanded geographical reach through partnerships in the Middle East could significantly boost Moderna's revenue and strengthen its market position.
Bear case
Despite the positive momentum, the company faces challenges. Declining revenues from COVID-19 vaccines and ongoing legal battles over mRNA patents could impact future profitability.
Positive Trial Results Boost Investor Confidence
Advertisement
Moderna's recent announcement regarding the successful Phase 3 INTerpath-001 trial of its personalized melanoma vaccine has generated excitement among investors. The trial met its primary endpoint, showcasing the potential of Moderna's mRNA technology beyond COVID-19 vaccines. This success is pivotal as it positions the company to diversify its revenue base and reduce reliance on pandemic-related products.
Strategic Expansion Efforts in the Middle East
In addition to its impressive trial results, Moderna is actively pursuing partnerships in the Middle East aimed at enhancing its manufacturing capabilities. These discussions indicate a strategic move to expand its global footprint and tap into new markets, which could lead to increased production capacity and revenue opportunities in the oncology sector.
Navigating Challenges Amidst Growth
While Moderna is experiencing a positive stock movement, investors should remain cautious. The company is still grappling with declining revenues from its COVID-19 vaccine and facing legal challenges related to mRNA patents. These factors could pose risks to its financial stability and future growth, making it crucial for investors to weigh potential rewards against existing challenges.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
